-

02:05:02 AM

PSTV Stock News

PSTV - Plus Therapeutics Inc

10/04/22 7:15 AM

Nasdaq : PSTV

clinical trial

Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT(TM) Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare

RHEA-AI

neutral

09/22/22 7:00 AM

Nasdaq : PSTV

Plus Therapeutics Executes $17.6 Million Award Contract with Cancer Prevention & Research Institute of Texas

Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022 CPRIT grant to support majority of 186 RNL targeted therapeutic development costs for leptomeningeal metastases program over three years; extends expected Company cash runway through 2025 AUSTIN, Texas, Sept.

RHEA-AI

very positive

09/12/22 7:00 AM

Nasdaq : PSTV

clinical trial

Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022

Phase 1 data indicates that direct administration of 186 RNL targeted radiotherapeutic is safe in patients with recurrent glioblastoma Statistically significant overall survival benefit observed with 186 RNL radiation doses over 100 Gray NIH-funded trial moving to Phase 2 to explore expanded dosing

RHEA-AI

very positive

09/08/22 7:00 AM

Nasdaq : PSTV

conferences

Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference

Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief Executive

RHEA-AI

neutral

09/06/22 7:00 AM

Nasdaq : PSTV

Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate

Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical

RHEA-AI

neutral

08/29/22 7:00 AM

Nasdaq : PSTV

Plus Therapeutics Announces Summary of FDA Meeting on Company's cGMP Manufacturing Process for Lead Drug Candidate

Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative,

RHEA-AI

neutral

08/23/22 7:00 AM

Nasdaq : PSTV

conferencesclinical trial

Plus Therapeutics to Present Data from ReSPECT-GBM(TM) Clinical Trial at the European Society for Medical Oncology Congress 2022

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from the Phase 1/2a

RHEA-AI

neutral

08/17/22 5:46 PM

Nasdaq : PSTV

Plus Therapeutics Awarded $17.6 Million from State of Texas

Plus Therapeutics,

RHEA-AI

neutral

08/15/22 7:00 AM

Nasdaq : PSTV

buyback

Plus Therapeutics Announces Share Repurchase Program

Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that its Board of Directors has approved a share repurchase

RHEA-AI

neutral

08/13/22 1:06 PM

Nasdaq : PSTV

clinical trial

Plus Therapeutics Presents Positive Data from Ongoing ReSPECT(TM) Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, yesterday presented positive data from two ongoing clinical

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

PSTV Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.plustherapeutics.com
CeoMarc Hedrick
Security namePlus Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees2021
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Surgical and Medical Instrument Manufacturing
Address4200 Marathon Blvd Ste 200
StateTexas
CityAustin
Zip78756-3433
CountryUS
Phone17372557194

About Plus Therapeutics Inc

Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers.